Showing results (331-340 of 363) with videos related to
Sort By:
Pageof 37
European Journal of Cancer (Oxford, England : 1990)|June 7, 2022
Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumoursNil A Schubert, Celine Y Chen, Ana Rodríguez, et al.JBMR Plus|September 30, 2025
Mechanisms of dexamethasone-induced bone toxicity in developing bone: a single-cell perspectiveKelly Warmink, Philip Lijnzaad, Stephanie A Schubert, et al.Veterinary and Comparative Oncology|September 7, 2013
Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogsC L Mariani, T A Schubert, R A House, et al.Journal of Neuromuscular Diseases|March 9, 2017
Proton Magnetic Resonance Spectroscopy Indicates Preserved Cerebral Biochemical Composition in Duchenne Muscular Dystrophy PatientsNathalie Doorenweerd, Melissa Hooijmans, Stephanie A Schubert, et al.Nature Communications|November 8, 2022
Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunityChun Jing Wang, Lina Petersone, Natalie M Edner, et al.Advanced Materials (Deerfield Beach, Fla.)|June 12, 2025
Adaptive Epitaxy of C-Si-Ge-Sn: Customizable Bulk and Quantum StructuresOmar Concepción, Ambrishkumar J Devaiya, Marvin H Zoellner, et al.Stroke|October 31, 2022
Optimal Cerebral Perfusion Pressure and Brain Tissue Oxygen in Aneurysmal Subarachnoid HemorrhageMurad Megjhani, Miriam Weiss, Jenna Ford, et al.Acta Neurochirurgica|March 31, 2019
Neurosurgical procedures performed during residency in Europe-preliminary numbers and time trendsMartin N Stienen, Jiri Bartek, Marcus A Czabanka, et al.Oncotarget|November 9, 2016
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cellsChristian B Schiller, Todd A Braciak, Nadja C Fenn, et al.Oncoimmunology|September 20, 2018
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsTodd A Braciak, Claudia C Roskopf, Sarah Wildenhain, et al.Pageof 37